EMED Technologies announced that its subsidiary has closed an $8 million equity financing round led by a multibillion dollar healthcare company, strengthening the unit’s balance sheet and positioning it for its next phase of strategic growth.
The funding will support organizational scale, product expansion, and broader strategic initiatives aligned with EMED’s long-term objectives in the drug delivery market. The raise reflects investor confidence in the subsidiary’s technology platform, operating model, execution capabilities, and long-term growth trajectory.
According to the company, the proceeds will be used to advance product innovation and expand operational capacity, enabling the subsidiary to pursue growth opportunities while maintaining disciplined execution. The financing is designed to reinforce the platform’s ability to scale without introducing risk or distraction to EMED’s established core business.
As part of EMED Technologies, the subsidiary benefits from the parent company’s global leadership, governance framework, and operational infrastructure. At the same time, it maintains an independent mandate, allowing it to focus on targeted initiatives that complement EMED’s core drug delivery operations. The structure is intended to preserve governance and operating discipline at the parent level while enabling adjacent opportunities to develop independently.
EMED Technologies, founded in 1991, designs, manufactures, and distributes medical devices focused on subcutaneous infusion systems. Its portfolio includes products such as the SCIg60, Infuset, and VersaRate, which are used to deliver medications and fluids for patients requiring home-based or chronic care treatments, including immune globulin therapy. The company’s systems are designed to improve patient safety, simplify drug administration, and support long-term therapies administered slowly and consistently.
The subsidiary’s expansion efforts are expected to support sustainable growth and broaden access to EMED’s existing devices and pipeline technologies, benefiting hundreds of thousands of patients globally.
KEY QUOTE:
“This capital raise represents an important milestone and reinforces the strategic value of this platform within EMED’s broader portfolio. It positions the organization to execute its growth strategy with discipline while maintaining operational flexibility.”
Paul Lambert, Chief Executive Officer of EMED Technologies
